Semaglutide (brand name Wegovy) is a GLP-1 receptor agonist that produced an average 14.9% body weight loss over 68 weeks in the landmark STEP 1 trial. This guide breaks down the clinical evidence, realistic timelines, dosing schedules, side effects, and what happens when you stop treatment.
In This Guide:
- What Is Semaglutide?
- How Does Semaglutide Cause Weight Loss?
- Clinical Trial Results: The STEP Program
- Realistic Weight Loss Timeline
- Semaglutide Dosing Schedule
- Side Effects: What the Data Shows
- What Happens When You Stop?
- Real-World Results vs. Clinical Trials
- Who Is Semaglutide Best For?
- Semaglutide vs. Other GLP-1 Peptides
- Frequently Asked Questions
- Key Takeaways
What Is Semaglutide?
Semaglutide is a synthetic peptide that mimics a hormone your body already makes called glucagon-like peptide-1 (GLP-1). Your gut releases natural GLP-1 after you eat, but it breaks down within 1–2 minutes. Semaglutide has been engineered with 94% structural similarity to human GLP-1 but with a much longer half-life of approximately 7 days, allowing once-weekly dosing.
The FDA approved semaglutide under two brand names: Ozempic (for type 2 diabetes at doses up to 2.0 mg) and Wegovy (for chronic weight management at 2.4 mg). While both contain the same active molecule, the weight loss indication specifically applies to the higher-dose Wegovy formulation.
Semaglutide has been studied in one of the largest clinical trial programs ever conducted for a weight loss treatment—the STEP (Semaglutide Treatment Effect in People with obesity) trials—which enrolled over 10,000 participants across multiple countries.
How Does Semaglutide Cause Weight Loss?
Semaglutide works through four interconnected mechanisms that collectively reduce how much you eat and how your body processes food.
1. Appetite Suppression Through the Brain
Semaglutide crosses into the brain and acts on the hypothalamus, your appetite control center. It stimulates POMC/CART neurons (which suppress hunger) and inhibits NPY/AgRP neurons (which drive hunger). It also helps restore leptin signaling, which is often disrupted in people with obesity (Mechanism study, PMC, 2024).
In simpler terms: semaglutide turns up the “I’m full” signals and turns down the “I’m hungry” signals in your brain.
2. Slowed Gastric Emptying
Semaglutide delays how quickly food leaves your stomach. Research shows it increases gastric half-emptying time from 118 minutes to 171 minutes—a 45% increase (Halawi et al., 2023). This means you feel full longer after meals and tend to eat smaller portions.
3. Reduced Food Reward Response
Brain imaging studies show that semaglutide suppresses activity in dopamine reward pathways during food consumption. This means high-calorie foods become less appealing—not through willpower but through altered brain chemistry (PMC, 2024).
Many users describe this as “food noise” going quiet. They stop thinking about food between meals and lose interest in snacking.
4. Blood Sugar Regulation
As a GLP-1 agonist, semaglutide stimulates insulin release and suppresses glucagon when blood sugar is elevated. This prevents the blood sugar crashes that trigger cravings and overeating in many people.
Clinical Trial Results: The STEP Program
The STEP trial program represents the strongest evidence base for semaglutide weight loss. Here are the key findings from each trial.
STEP 1: The Landmark Trial
The STEP 1 trial enrolled 1,961 adults with obesity (BMI 30 or higher) or overweight with at least one weight-related condition, none of whom had diabetes. Participants received either semaglutide 2.4 mg weekly or placebo for 68 weeks, alongside lifestyle intervention (Wilding et al., NEJM, 2021).
Results at 68 weeks:
| Outcome | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Average weight loss | 14.9% | 2.4% |
| Achieved 5%+ weight loss | 86.4% | 31.5% |
| Achieved 10%+ weight loss | 69.1% | 12.0% |
| Achieved 15%+ weight loss | 50.5% | 4.9% |
These numbers made headlines because no previous drug had consistently produced double-digit percentage weight loss in a majority of participants.
STEP 2: With Type 2 Diabetes
People with type 2 diabetes typically lose less weight on GLP-1 medications due to insulin resistance and altered metabolic pathways. The STEP 2 trial confirmed this pattern: participants lost an average of 9.6% body weight with semaglutide versus 3.4% with placebo over 68 weeks (Davies et al., Lancet, 2021).
STEP 3: Combined With Intensive Therapy
When semaglutide was paired with an initial low-calorie diet and intensive behavioral counseling, participants achieved 16.0% weight loss versus 5.7% with placebo—the highest result in the STEP program (Wadden et al., JAMA, 2021).
STEP 5: Two-Year Data
The STEP 5 trial provided the longest data, following participants for 104 weeks (2 years). Weight loss was 15.2% with semaglutide versus 2.6% with placebo. This confirmed that weight loss is maintained through year two of treatment, not just an initial honeymoon effect (Garvey et al., Nature Medicine, 2022).
STEP 8: Semaglutide vs. Liraglutide (Head-to-Head)
Directly compared to liraglutide (Saxenda), another GLP-1 weight loss drug, semaglutide delivered dramatically superior results: 15.8% versus 6.4% weight loss. Participants on semaglutide were 6.3 times more likely to lose 10% or more of their body weight (Rubino et al., JAMA, 2022).
SELECT: Cardiovascular Benefits
The massive SELECT trial (17,604 participants with existing cardiovascular disease) showed semaglutide reduced major adverse cardiovascular events by 20% alongside a 10.2% weight loss over approximately 4 years (Lincoff et al., NEJM, 2023). This was the first time a weight loss medication demonstrated cardiovascular risk reduction in a dedicated outcomes trial.
Realistic Weight Loss Timeline: Week by Week
Based on aggregated data from the STEP trials, here is what a typical weight loss trajectory looks like with semaglutide 2.4 mg:
| Timepoint | Expected Weight Loss | What Is Happening |
|---|---|---|
| Weeks 1–4 | 2–3% | Starting dose (0.25 mg). Appetite begins decreasing. Some nausea possible. |
| Weeks 5–8 | 5–6% | Dose increases to 0.5 mg. Noticeable appetite reduction. Food noise quieting. |
| Weeks 9–12 | 7–10% | Dose at 1.0 mg. Significant appetite change. Clothes fitting differently. |
| Weeks 13–16 | 10–12% | Dose at 1.7 mg. Approaching maintenance dose. Weight loss accelerating. |
| Weeks 17–26 | 12–14% | Full dose 2.4 mg. Rapid weight loss phase. |
| Months 7–12 | 14–16% | Weight loss rate slows as body approaches new set point. |
| Year 2 (STEP 5) | ~15% | Weight maintained with continued use. |
Important context: These are averages. Individual results vary significantly. Some people lose 20% or more while others lose under 10%. The data from STEP 1 showed that roughly half of participants lost more than 15% of their body weight, while about 14% lost less than 5%.
The steepest weight loss typically occurs between weeks 8 and 28, then gradually levels off as the body reaches a new equilibrium.
Semaglutide Dosing Schedule
Semaglutide follows a 16-week dose escalation designed to minimize side effects. Jumping straight to the full dose causes severe gastrointestinal symptoms in most people.
| Period | Weekly Dose | Purpose |
|---|---|---|
| Weeks 1–4 | 0.25 mg | GI tract adaptation. Minimal weight loss expected. |
| Weeks 5–8 | 0.50 mg | First increase. Appetite effects becoming noticeable. |
| Weeks 9–12 | 1.0 mg | Second increase. Significant appetite suppression. |
| Weeks 13–16 | 1.7 mg | Third increase. Approaching therapeutic range. |
| Week 17 onward | 2.4 mg | Full maintenance dose. Maximum efficacy. |
Dosing tips from the clinical data:
- If you cannot tolerate a dose increase, stay at the current dose for an additional 4 weeks before trying again.
- Semaglutide is injected subcutaneously once weekly, on the same day each week.
- The injection can be given in the abdomen, thigh, or upper arm. See our guide to peptide injection for detailed technique instructions.
- Store pens in the refrigerator (36–46°F / 2–8°C). In-use pens can be kept at room temperature for up to 28 days.
Side Effects: What the Data Shows
Gastrointestinal side effects are the most common with semaglutide. Pooled data from STEP 1–3 provides detailed frequency information (Wharton et al., 2022):
GI Side Effect Frequency
| Side Effect | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Nausea | 43.9% | 16.1% |
| Diarrhea | 29.7% | 15.9% |
| Vomiting | 24.5% | 6.3% |
| Constipation | 24.2% | 11.1% |
The Good News About Side Effects
- 99.5% of GI events were non-serious
- 98.1% were rated as mild-to-moderate in severity
- Median duration of nausea episodes: 8 days
- Median duration of diarrhea episodes: 3 days
- Median duration of vomiting episodes: 2 days
- GI side effects peak around week 20 during dose escalation and decline after that
- Only 0.8–4.5% of participants discontinued treatment because of GI side effects
Less Common Side Effects
- Gallstones: 1.6% with semaglutide versus 0.7% with placebo. Rapid weight loss from any cause increases gallstone risk.
- Injection site reactions: Mild and infrequent in clinical trials.
- Headache and fatigue: Occasionally reported, especially during early treatment.
- Pancreatitis: No significant difference from placebo in clinical trials, but it remains a theoretical concern that healthcare providers monitor for.
Who Should Not Use Semaglutide
Based on safety data and prescribing information, semaglutide is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. It should be used with caution in people with a history of pancreatitis (PMC, 2021).
What Happens When You Stop Semaglutide?
This is one of the most important sections of this guide because the data here is sometimes overlooked.
The STEP 1 Extension Study
After the initial 68-week STEP 1 trial ended, researchers followed participants for an additional year without treatment. The results were striking (Wilding et al., 2022):
- Weight loss during treatment (68 weeks): -17.3%
- Weight regain after stopping (68–120 weeks): +11.6 percentage points
- Net weight loss at week 120 (1 year after stopping): -5.6%
Participants regained approximately two-thirds of their prior weight loss within one year of stopping semaglutide.
The STEP 4 Withdrawal Data
The STEP 4 trial was specifically designed to test what happens when treatment stops. After 20 weeks of semaglutide (with -10.6% weight loss), participants were randomized to either continue or switch to placebo (Rubino et al., JAMA, 2021):
- Continued semaglutide: Lost an additional 7.9% (total -17.4%)
- Switched to placebo: Regained 6.9%
The 14.8 percentage-point gap between groups confirms that ongoing treatment is needed to maintain results.
Why Weight Returns
This is not a personal failing. Obesity involves disrupted neurohormonal signaling. Semaglutide corrects the appetite and satiety signals that drive overeating, but those disruptions return when the medication stops. This is similar to how blood pressure returns when you stop blood pressure medication.
Most researchers and clinicians now consider obesity a chronic condition that requires ongoing management, whether through medication, lifestyle modifications, or a combination of approaches.
Real-World Results vs. Clinical Trials
Clinical trials use strict protocols, close monitoring, and highly motivated participants. Real-world results are typically lower but still clinically meaningful.
Clinical Trial Average (STEP Program)
- Without diabetes: 14.9–17.4% weight loss at 68 weeks
- With type 2 diabetes: 9.6% at 68 weeks
Real-World Evidence
The SCOPE study tracked patients prescribed semaglutide in routine clinical practice (PMC, 2024):
| Outcome (6 months) | Real-World Result |
|---|---|
| Average weight loss | 10.0% |
| Achieved 5%+ weight loss | 79.0% |
| Achieved 10%+ weight loss | 48.1% |
| Achieved 15%+ weight loss | 19.0% |
Why the Gap Exists
| Factor | Clinical Trial | Real World |
|---|---|---|
| Adherence | Protocol-enforced weekly dosing | Variable. Missed doses common. |
| Dose achieved | All participants reach 2.4 mg | Some stay on lower doses |
| Lifestyle support | Structured counseling provided | Varies widely |
| Follow-up | Complete data collection | Many patients lost to follow-up |
The key takeaway: real-world results of 8–13% weight loss at 6–12 months are realistic and still exceed what most other interventions achieve.
Who Is Semaglutide Best For?
Based on the clinical trial populations and outcomes data, semaglutide may be most appropriate for:
- People with a BMI of 30 or higher (or 27 or higher with at least one weight-related condition)
- Those who have tried diet and exercise without achieving clinically meaningful weight loss
- People who can commit to long-term use, since stopping typically leads to weight regain
- People without contraindications, including no history of medullary thyroid carcinoma, MEN2, or active pancreatitis
Semaglutide may be less effective for people with type 2 diabetes (expect ~10% vs ~15% weight loss) and should be used with caution alongside other medications that lower blood sugar.
Semaglutide vs. Other GLP-1 Peptides
Semaglutide is not the only GLP-1 receptor agonist available for weight management. Here is how it compares to other options based on clinical trial data:
| Feature | Semaglutide (Wegovy) | Tirzepatide (Zepbound) | Liraglutide (Saxenda) |
|---|---|---|---|
| Mechanism | GLP-1 agonist | GLP-1 + GIP dual agonist | GLP-1 agonist |
| Avg. Weight Loss | 14.9% (68 weeks) | 20.9% (72 weeks) | 8.0% (56 weeks) |
| Dosing | Once weekly injection | Once weekly injection | Daily injection |
| FDA Approved for Weight Loss | Yes (Wegovy, 2021) | Yes (Zepbound, 2023) | Yes (Saxenda, 2014) |
| Cardiovascular Benefit | Yes (SELECT trial) | Under investigation | Not demonstrated |
| GI Side Effects | Moderate (nausea ~44%) | Moderate (nausea ~24–33%) | High (nausea ~40%) |
| Research Maturity | Extensive (8+ major trials) | Growing (SURMOUNT program) | Extensive (10+ years data) |
Tirzepatide shows greater average weight loss in trials, but semaglutide has the most extensive long-term safety data, including the landmark SELECT cardiovascular outcomes trial. For a detailed comparison, see our best peptides for weight loss guide.
Frequently Asked Questions
How much weight can I lose on semaglutide?
Clinical trials show average weight loss of 14.9% of body weight over 68 weeks at the 2.4 mg dose. For a 220-pound person, that translates to roughly 33 pounds. Individual results vary—about one-third of participants in the STEP 1 trial lost 20% or more of their body weight (Wilding et al., 2021).
How fast does semaglutide work for weight loss?
Most people notice appetite changes within the first 1–2 weeks. Measurable weight loss typically begins by weeks 4–8, with the most rapid loss occurring between months 2 and 6. The full therapeutic dose (2.4 mg) is not reached until week 16 due to the gradual dose escalation protocol.
How long do you need to take semaglutide?
Current evidence suggests semaglutide works best as a long-term treatment. The STEP 1 extension study showed that participants who stopped semaglutide at 68 weeks regained approximately two-thirds of their lost weight within one year (Wilding et al., 2022). Many researchers now view obesity as a chronic condition requiring ongoing management.
How do you manage nausea on semaglutide?
Nausea is the most common side effect, affecting about 44% of participants in trials. Strategies that may help include: eating smaller, more frequent meals; avoiding high-fat or greasy foods; staying hydrated; eating slowly; and following the prescribed dose escalation schedule. For most people, nausea improves significantly after the first 8–12 weeks as the body adjusts.
Can semaglutide be combined with other peptides?
Some researchers are investigating combinations of GLP-1 agonists with other compounds. Tirzepatide, which combines GLP-1 and GIP receptor activity, has shown greater weight loss than semaglutide alone. However, combining multiple peptides should only be done under medical supervision. See our protocols page for more information on peptide combinations.
Is semaglutide safe long-term?
The SELECT trial followed over 17,600 participants for up to 5 years, providing the longest safety data available. That study found semaglutide not only to be well-tolerated long-term but also associated with a 20% reduction in major cardiovascular events (Lincoff et al., 2023). The most common long-term side effects remain gastrointestinal in nature.
What is the difference between Ozempic and Wegovy?
Both contain semaglutide but are approved for different uses. Ozempic is approved for type 2 diabetes management at doses up to 2.0 mg weekly. Wegovy is approved specifically for weight management at a higher dose of 2.4 mg weekly. The active ingredient is identical—the difference is the indication, maximum dose, and insurance coverage pathway.
Does semaglutide cause muscle loss?
Weight loss from any method typically involves some lean mass loss alongside fat loss. In the STEP 1 trial, approximately 40% of total weight lost was lean mass. Resistance training and adequate protein intake (1.2–1.6 g/kg body weight daily) are recommended to help preserve muscle during semaglutide treatment (Wharton et al., 2022).
How much does semaglutide cost?
The branded Wegovy list price is approximately $1,350 per month in the United States without insurance. Compounded semaglutide has historically been available at lower cost, though availability has changed with FDA regulatory updates. Insurance coverage varies widely—some plans cover Wegovy for qualifying BMI, while others exclude weight management medications. Check our legal status guide for the latest regulatory information.
Key Takeaways
- Proven efficacy: Semaglutide produces an average 14.9% body weight loss over 68 weeks, with one-third of users losing 20% or more
- Beyond weight loss: The SELECT trial demonstrated a 20% reduction in cardiovascular events, establishing benefits beyond the scale
- Gradual dosing matters: The 16-week dose escalation protocol significantly reduces side effects and improves tolerability
- GI side effects are manageable: Nausea affects ~44% of users initially but typically resolves within 8–12 weeks
- Long-term commitment: Weight regain occurs in most people who discontinue—plan for sustained use or a structured transition strategy
- Real-world results are slightly lower: Expect 10–12% weight loss in practice versus 14.9% in trials, due to adherence and lifestyle factors
- Preserve muscle: Combine semaglutide with resistance training and adequate protein (1.2–1.6 g/kg/day) to minimize lean mass loss
- Medical supervision is essential: Semaglutide is a prescription medication that requires proper medical oversight for safe and effective use
Related Articles
- Best Peptides for Weight Loss in 2026: Science-Backed Rankings
- Peptides for Weight Loss: How GLP-1 Peptides Actually Work
- What Are Peptides? The Complete Beginner’s Guide
- Are Peptides Legal in 2026? Complete Regulatory Guide
- How to Inject Peptides: Fear-Free Beginner Guide
This content is for educational and informational purposes only. It is not intended as medical advice. Peptides discussed are research compounds not approved by the FDA for human therapeutic use. Always consult a qualified healthcare professional before making health decisions.